05.09.25 -- The Serious Business Of Working With CDMOs At Phase 2

We know how tough it can be to find the right CDMO, especially when capacity is tight and timelines are critical. That's why you’ll find our collection of recent Outsourced Pharma Capacity Update presentations so valuable. Our April Partners Week Update details the latest capabilities and available capacity from 40 leading CDMOs – and you can experience it all from the convenience of your screen. View the on-demand sessions for the modalities that fit your needs.

In 2025, CMOs will navigate Annex 1 compliance, the BioSecure Act’s uncertainty, AI-driven drug development, supply chain challenges from tariffs, and pandemic preparedness strategies.

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and adherence while expanding the therapeutic market.

Explore the importance of particle size characterization and the advanced analytical techniques employed to assess micronized particles effectively.

When understood and managed properly, subjectivity becomes a source of creativity. It reveals hidden hazards and unlocks more effective risk controls.

Advances in synthetic biology and supporting technologies have expanded fermentation's suitability for a wide range of applications.

Examine several important factors needed to effectively support oral solid dosage therapeutic manufacturing and overcome the complexities involved.

Review this case to learn how one solid dispersion technology lowered patients' pill burdens and demonstrated an improved therapeutic response for Galeterone.

Discover how CDMOs can help you achieve and maintain CMC compliance throughout the drug development lifecycle. Outsourced Pharma Live will explore how to leverage CDMO expertise in process optimization, documentation, and regulatory submissions. Learn practical strategies to align your CMC goals with CDMO capabilities to accelerate development and ensure successful drug launches. Registration is free thanks to the support of Curia.

Accelerate your pharmaceutical development with end-to-end support, global softgel expertise, and the strategic advantages of a New Zealand-based manufacturing partner.

Altasciences' manufacturing (CDMO) team provides tailored solutions for each phase of your drug development program. From discovery to market ― they’ve got you covered!